Imperial College London
Portrait Picture

DrRobertKypta

Faculty of Medicine, Department of Surgery & Cancer

Senior Lecturer in Cancer Biology
 
 
 
//

Contact

 

r.kypta Website

 
 
//

Location

 

4007Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Murillo-Garzón:2017:10.1038/nrurol.2017.144,
author = {Murillo-Garzón, V and Kypta, R},
doi = {10.1038/nrurol.2017.144},
journal = {Nature Reviews Urology},
pages = {683--696},
title = {WNT signalling in prostate cancer},
url = {http://dx.doi.org/10.1038/nrurol.2017.144},
volume = {14},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential importance of genetic and epigenetic changes observed in WNT signalling pathway components in prostate tumours-particularly in the development of castration-resistant prostate cancer. WNT signalling is also important in the prostate tumour microenvironment, in which WNT proteins secreted by the tumour stroma promote resistance to therapy, and in prostate cancer stem or progenitor cells, in which WNT-β-catenin signals promote self-renewal or expansion. Preclinical studies have demonstrated the potential of inhibitors that target WNT receptor complexes at the cell membrane or that block the interaction of β-catenin with lymphoid enhancer-binding factor 1 and the androgen receptor, in preventing prostate cancer progression. Some WNT signalling inhibitors are in phase I trials, but they have yet to be tested in patients with prostate cancer.
AU  - Murillo-Garzón,V
AU  - Kypta,R
DO  - 10.1038/nrurol.2017.144
EP  - 696
PY  - 2017///
SN  - 1743-4270
SP  - 683
TI  - WNT signalling in prostate cancer
T2  - Nature Reviews Urology
UR  - http://dx.doi.org/10.1038/nrurol.2017.144
UR  - http://hdl.handle.net/10044/1/57966
VL  - 14
ER  -
Download